|Day's Range||320.74 - 321.97|
|52 Week Range||203.63 - 321.97|
|PE Ratio (TTM)||40.97|
|Dividend & Yield||1.04 (0.32%)|
|1y Target Est||N/A|
Growing adoption of the company's flagship Lutonix drug coated-balloon is expected to benefit C.R. Bard's (BCR) performance in the second quarter.
On Jul 7, we issued an updated research report on Franklin Lakes, NJ-based Becton, Dickinson and Company (BDX).
Medical device maker AngioDynamics filed a lawsuit alleging its competitor, C.R. Bard, is violating antitrust laws with the sale of its catheters. AngioDynamics (ANGO) claims in the lawsuit C.R. Bard (BCR:NYSE) is illegally tying its catheter tip location systems to its own line of catheters, preventing customers from using other catheters from other companies.